OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Dr. Naing on the Potential Implications of Immune-Related Adverse Effects in Cancer

Feb 23, 2021
Aung Naing, MD, FACP
Video

In Partnership With:

Aung Naing, MD, FACP, discusses potential immune-related adverse effects in oncology.

Aung Naing, MD, FACP, associate member, The University of Texas Graduate School of Biomedical Sciences, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses potential immune-related adverse effects (irAEs) in oncology.

irAEs can affect any organ system. Some of the most common irAEs include dermatitis, enterocolitis, and hepatitis, says Naing. Although irAEs are often mild and reversible, they can be unpredictable and sometimes lead to significant complications for patients. Some events can progress rapidly and develop into serious, grade 3 or higher toxicities that can be life-threatening or fatal. Some patients, particularly those who are elderly, can experience significant detriment to their quality of life from debilitating irAEs and sometimes require treatment discontinuation, Naing explains. As such, irAEs can negatively impact disease control and potentially lead to permanent organ damage or treatment-related death.

Finally, patients receiving checkpoint inhibitors who are at risk of developing irAEs require multidisciplinary management, frequent hospital visits, and potentially prolonged hospitalization, says Naing. Moreover, prolonged hospitalization can lead to increased health care cost and financial toxicity, concludes Naing.

Related Videos
Wesley J. Talcott, MD, MBA
Tiago Biachi, MD, PhD
Kevin Kayvan Zarrabi, MD, MS, FACP
Arutha Kulasinghe, PhD
Andrea Billè, MD
Tian Zhang, MD, MHS
Anand Narayan, MD, PhD
J. Randolph (Randy) Hecht, MD
Qian (Janie) Qin, MD
Related Content

Phase 1 Trial Seeks to Determine the Role for Upfront Uproleselan in AML

September 27th 2023

Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST

September 18th 2023

Pembrolizumab/Lenvatinib Regimens Miss Survival End Points in Metastatic NSCLC

September 22nd 2023

Camidge and Vokes Reflect on Research Journeys, Team Building, and Mentorship

August 24th 2023

Perioperative Nivolumab Plus Chemotherapy Improves EFS in Resectable NSCLC

September 22nd 2023

Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML

September 21st 2023

Phase 1 Trial Seeks to Determine the Role for Upfront Uproleselan in AML

September 27th 2023

Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST

September 18th 2023

Pembrolizumab/Lenvatinib Regimens Miss Survival End Points in Metastatic NSCLC

September 22nd 2023

Camidge and Vokes Reflect on Research Journeys, Team Building, and Mentorship

August 24th 2023

Perioperative Nivolumab Plus Chemotherapy Improves EFS in Resectable NSCLC

September 22nd 2023

Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML

September 21st 2023

Phase 1 Trial Seeks to Determine the Role for Upfront Uproleselan in AML

September 27th 2023

Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST

September 18th 2023

Pembrolizumab/Lenvatinib Regimens Miss Survival End Points in Metastatic NSCLC

September 22nd 2023

Camidge and Vokes Reflect on Research Journeys, Team Building, and Mentorship

August 24th 2023

Perioperative Nivolumab Plus Chemotherapy Improves EFS in Resectable NSCLC

September 22nd 2023

Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML

September 21st 2023
Related Content
Advertisement
Naval G. Daver, MD

Phase 1 Trial Seeks to Determine the Role for Upfront Uproleselan in AML

September 27th 2023
Article
Robin Jones, MD, MRCP; Neeta Somaiah, MD

Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST

September 18th 2023
Podcast
Gregory Lubiniecki, MD

Pembrolizumab/Lenvatinib Regimens Miss Survival End Points in Metastatic NSCLC

September 22nd 2023
Article
D. Ross Camidge, MD, PhD; Natalie Vokes, MD

Camidge and Vokes Reflect on Research Journeys, Team Building, and Mentorship

August 24th 2023
Podcast
Perioperative Nivolumab Plus Chemotherapy in NSCLC | Image   Credit: © anusorn - stock.adobe.com

Perioperative Nivolumab Plus Chemotherapy Improves EFS in Resectable NSCLC

September 22nd 2023
Article
Courtney D. DiNardo, MD, MSCE

Triplets With Azacitidine/Venetoclax Aim to Improve Responses in AML

September 21st 2023
Article

Latest Conference Coverage

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact